ASCO 2019: SurVaxM with Standard Therapy in Newly Diagnosed Glioblastoma: Phase II Trial Update
SurVaxM is a cancer immunotherapy vaccine (boosts the body’s own immune system to fight cancer cells) designed to target and attack cancer cells with survivin